These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

474 related articles for article (PubMed ID: 30124753)

  • 1. Quality of life with talazoparib versus physician's choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial.
    Ettl J; Quek RGW; Lee KH; Rugo HS; Hurvitz S; Gonçalves A; Fehrenbacher L; Yerushalmi R; Mina LA; Martin M; Roché H; Im YH; Markova D; Bhattacharyya H; Hannah AL; Eiermann W; Blum JL; Litton JK
    Ann Oncol; 2018 Sep; 29(9):1939-1947. PubMed ID: 30124753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quality of life with talazoparib after platinum or multiple cytotoxic non-platinum regimens in patients with advanced breast cancer and germline BRCA1/2 mutations: patient-reported outcomes from the ABRAZO phase 2 trial.
    Hurvitz SA; Quek RGW; Turner NC; Telli ML; Rugo HS; Mailliez A; Ettl J; Grischke E; Mina LA; Balmaña J; Fasching PA; Bhattacharyya H; Hannah AL; Robson ME; Wardley AM
    Eur J Cancer; 2018 Nov; 104():160-168. PubMed ID: 30359909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.
    Litton JK; Rugo HS; Ettl J; Hurvitz SA; Gonçalves A; Lee KH; Fehrenbacher L; Yerushalmi R; Mina LA; Martin M; Roché H; Im YH; Quek RGW; Markova D; Tudor IC; Hannah AL; Eiermann W; Blum JL
    N Engl J Med; 2018 Aug; 379(8):753-763. PubMed ID: 30110579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Talazoparib Versus Chemotherapy in Patients with HER2-negative Advanced Breast Cancer and a Germline BRCA1/2 Mutation Enrolled in Asian Countries: Exploratory Subgroup Analysis of the Phase III EMBRACA Trial.
    Lee KH; Sohn J; Goodwin A; Usari T; Lanzalone S; Im SA; Kim SB
    Cancer Res Treat; 2021 Oct; 53(4):1084-1095. PubMed ID: 33781053
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial.
    Litton JK; Hurvitz SA; Mina LA; Rugo HS; Lee KH; Gonçalves A; Diab S; Woodward N; Goodwin A; Yerushalmi R; Roché H; Im YH; Eiermann W; Quek RGW; Usari T; Lanzalone S; Czibere A; Blum JL; Martin M; Ettl J
    Ann Oncol; 2020 Nov; 31(11):1526-1535. PubMed ID: 32828825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial.
    Robson M; Ruddy KJ; Im SA; Senkus E; Xu B; Domchek SM; Masuda N; Li W; Tung N; Armstrong A; Delaloge S; Bannister W; Goessl C; Degboe A; Hettle R; Conte P
    Eur J Cancer; 2019 Oct; 120():20-30. PubMed ID: 31446213
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Talazoparib in Patients with a Germline BRCA-Mutated Advanced Breast Cancer: Detailed Safety Analyses from the Phase III EMBRACA Trial.
    Hurvitz SA; Gonçalves A; Rugo HS; Lee KH; Fehrenbacher L; Mina LA; Diab S; Blum JL; Chakrabarti J; Elmeliegy M; DeAnnuntis L; Gauthier E; Czibere A; Tudor IC; Quek RGW; Litton JK; Ettl J
    Oncologist; 2020 Mar; 25(3):e439-e450. PubMed ID: 32162822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quality of life with cemiplimab plus chemotherapy for first-line treatment of advanced non-small cell lung cancer: Patient-reported outcomes from phase 3 EMPOWER-Lung 3.
    Makharadze T; Quek RGW; Melkadze T; Gogishvili M; Ivanescu C; Giorgadze D; Dvorkin M; Penkov K; Laktionov K; Nemsadze G; Nechaeva M; Rozhkova I; Kalinka E; Gessner C; Moreno-Jaime B; Passalacqua R; Konidaris G; Rietschel P; Gullo G
    Cancer; 2023 Jul; 129(14):2256-2265. PubMed ID: 37151113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): patient-reported outcomes from a randomised, open-label, multicentre, phase 3 trial.
    Fehm T; Cottone F; Dunton K; André F; Krop I; Park YH; De Laurentiis M; Miyoshi Y; Armstrong A; Borrego MR; Yerushalmi R; Duhoux FP; Takano T; Lu W; Egorov A; Kim SB
    Lancet Oncol; 2024 May; 25(5):614-625. PubMed ID: 38697155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib.
    Hammel P; Kindler HL; Reni M; Van Cutsem E; Macarulla T; Hall MJ; Park JO; Hochhauser D; Arnold D; Oh DY; Reinacher-Schick A; Tortora G; Algül H; O'Reilly EM; McGuinness D; Cui KY; Joo S; Yoo HK; Patel N; Golan T;
    Ann Oncol; 2019 Dec; 30(12):1959-1968. PubMed ID: 31562758
    [TBL] [Abstract][Full Text] [Related]  

  • 11. OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer.
    Robson ME; Tung N; Conte P; Im SA; Senkus E; Xu B; Masuda N; Delaloge S; Li W; Armstrong A; Wu W; Goessl C; Runswick S; Domchek SM
    Ann Oncol; 2019 Apr; 30(4):558-566. PubMed ID: 30689707
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of talazoparib for patients with germline BRCA1/2 mutated HER2-negative advanced breast cancer in China and the US.
    Pan J; Ren N; Ren L; Yang Y; Xu Q
    Sci Rep; 2024 Jun; 14(1):13935. PubMed ID: 38886516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA1- or BRCA2-mutated HER2-negative advanced breast cancer as first line treatment (REVIVAL): study protocol for a randomized controlled trial.
    Schouten PC; Dackus GM; Marchetti S; van Tinteren H; Sonke GS; Schellens JH; Linn SC
    Trials; 2016 Jun; 17(1):293. PubMed ID: 27323902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline
    Litton JK; Scoggins ME; Hess KR; Adrada BE; Murthy RK; Damodaran S; DeSnyder SM; Brewster AM; Barcenas CH; Valero V; Whitman GJ; Schwartz-Gomez J; Mittendorf EA; Thompson AM; Helgason T; Ibrahim N; Piwnica-Worms H; Moulder SL; Arun BK
    J Clin Oncol; 2020 Feb; 38(5):388-394. PubMed ID: 31461380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes in Clinically Relevant Patient Subgroups From the EMBRACA Study: Talazoparib vs Physician's Choice Standard-of-Care Chemotherapy.
    Rugo HS; Ettl J; Hurvitz SA; Gonçalves A; Lee KH; Fehrenbacher L; Mina LA; Diab S; Woodward NE; Yerushalmi R; Goodwin A; Blum JL; Martin M; Quek RGW; Tudor IC; Bhattacharyya H; Gauthier E; Litton JK; Eiermann W
    JNCI Cancer Spectr; 2020 Feb; 4(1):pkz085. PubMed ID: 32337496
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exposure-Safety Analyses of Talazoparib in Patients With Advanced Breast Cancer and Germline BRCA1/2 Mutations in the EMBRACA and ABRAZO Trials.
    Elmeliegy M; Yu Y; Litton JK; Czibere A; Wilson GG; Tudor IC; Zheng J; Wang DD
    J Clin Pharmacol; 2020 Oct; 60(10):1334-1343. PubMed ID: 32468645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world patient-reported outcomes and physician satisfaction with poly (ADP-ribose) polymerase inhibitors versus chemotherapy in patients with germline BRCA1/2-mutated human epidermal growth factor receptor 2-negative advanced breast cancer from the United States, Europe, and Israel.
    Mahtani R; Niyazov A; Arondekar B; Lewis K; Rider A; Massey L; Lux MP
    BMC Cancer; 2022 Dec; 22(1):1343. PubMed ID: 36550413
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline
    de Bono J; Ramanathan RK; Mina L; Chugh R; Glaspy J; Rafii S; Kaye S; Sachdev J; Heymach J; Smith DC; Henshaw JW; Herriott A; Patterson M; Curtin NJ; Byers LA; Wainberg ZA
    Cancer Discov; 2017 Jun; 7(6):620-629. PubMed ID: 28242752
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial.
    Harbeck N; Iyer S; Turner N; Cristofanilli M; Ro J; André F; Loi S; Verma S; Iwata H; Bhattacharyya H; Puyana Theall K; Bartlett CH; Loibl S
    Ann Oncol; 2016 Jun; 27(6):1047-1054. PubMed ID: 27029704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Talazoparib Exposure-Efficacy Analysis in Patients With Advanced Breast Cancer and Germline BRCA1/2 Mutations in the EMBRACA Trial.
    Yu Y; Elmeliegy M; Litton JK; Tudor IC; Czibere A; Zheng J; Wang DD
    J Clin Pharmacol; 2020 Oct; 60(10):1324-1333. PubMed ID: 32468579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.